Scholars Central

Case reportPublished 4 Aug 2024

SMARCA4 Deficient Tumours of Ovary and Uterus: 2 Case Reports with Review of Literature

Authors: Lekshmi R Shenoi, Mariya Zehra, Sunil K Regmi, Syed Nisar Ahmad

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Swi/Snf Related,Matrix Associated, Actin Dependent Regulator Of Chromatin,Subfamily A,Member 4 (SMARCA4-deficient) tumors are typically aggressive, characterized by undifferentiated round cells or rhabdoid features histopathologically. These tumors are rarer compared to their other epithelial counterparts and generally have a poorer prognosis. Here, we report two cases with mutations in the SMARCA4 gene. The first case involves a 29-year-old woman with Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT). She presented with lower abdominal pain, and Contrast Enhanced Compututed Tomography (CECT) imaging indicated widespread abdominopelvic disease with left supraclavicular and axillary lymph nodes. A biopsy revealed undifferentiated carcinoma with loss of Brahma-Related Gene-1 (BRG-1) and retention of Integrase Interactor-1 (INI-1) on Immunohistochemistry (IHC). Despite receiving three cycles of etoposide/carboplatin and seven cycles of a four-drug regimen (cisplatin/adriamycin/ etoposide/cyclophosphamide), she succumbed to the disease while on supportive care, with an overall survival of 13 months. The second case involves a 38-years-old woman with SMARCA4-Deficient Uterine Sarcoma (SDUS). She presented with lower abdominal pain, an enlarged uterus, thickened endometrium, and bilateral ovarian and nodal deposits. An omental biopsy revealed large tumor cells with vesicular nuclei, and IHC suggested diffuse expression of Cluster Of Differentiation 99 (CD99), with similar BRG-1 loss and INI-1 retention. She received two lines of chemotherapy (gemcitabine/docetaxel and adriamycin/ifosfamide) but unfortunately succumbed to the disease within four months of diagnosis. Both patients presented at advanced stages and were only able to receive conventional chemotherapy due to financial constraints. Newer promising therapies need to be explored in such rare cases, where treatment protocols are still under evaluation for standard of care and efficacy, wherever resources permit.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Oncology: Case Reports.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Oncology: Case Reports
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Lekshmi R Shenoi”
  • BylineArticles whose byline prints “Mariya Zehra”
  • BylineArticles whose byline prints “Sunil K Regmi”
  • BylineArticles whose byline prints “Syed Nisar Ahmad”